Skip to content

Clinical Trial Scheme of Shu Gan yi Yang Capsule

a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency)

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03290313
Enrollment
160
Registered
2017-09-21
Start date
2017-09-30
Completion date
2018-12-31
Last updated
2017-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression With Erectile Dysfunction

Keywords

Depression, erectile dysfunction, shu gan yi yang

Brief summary

Shu gan yi yang capsule is made of traditional Chinese medicine Guizhou Yi Bai pharmaceutical Limited by Share Ltd, for liver and kidney deficiency and liver and kidney deficiency and blood stasis caused by functional impotence and mild arterial insufficiency in impotence, impotence, flaccid penis not hard or lift and not firm, chest deep sigh, chest fullness, soreness and weakness of waist and knees, pale tongue or petechiae, pulse string or string. The choice of depression associated with erectile dysfunction patients, and investigate its effect.In this study, patients with depression and erectile dysfunction were selected and the efficacy was investigated

Detailed description

The study is a placebo-controlled clinical trial, 160 patients with depression and erectile dysfunction were selected for 8 weeks of observation

Interventions

DRUGshu gan yi yang capsule

Patients who did not use any antidepressants were given normal clinical medication; Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication

DRUGshu gan yi yang capsule simulation agent

Patients who did not use any antidepressants were given normal clinical medication; Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication

OTHERSupportive psychotherapy

Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial

Sponsors

Guizhou Yi Bai Pharmaceutical Co., Ltd.
CollaboratorUNKNOWN
Peking University Sixth Hospital
CollaboratorOTHER
Beijing HuiLongGuan Hospital
CollaboratorOTHER
Beijing Hospital of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
22 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Meet the diagnostic criteria for Western medicine in depression; 2. MADRS score ≥ 12 points and \<30 points; 3. Diagnostic criteria for western medicine in line with erectile dysfunction,IIEF -5≤21points; 4. TCM syndrome differentiation of liver depression and kidney deficiency in accordance with depression and erectile dysfunction; 5. Male subjects, aged 22-65 years old; 6. Patients who have not been treated with antidepressants or have been treated with antidepressants for more than 1 months and have reached treatment doses have no need to adjust their medications and dosages within 2 months; 7. The relationship between patients and sexual partners is stable (at least in the last 6 months); 8. Volunteer to participate in clinical trials, and sign informed consent.

Exclusion criteria

1. A patient with major depressive disorder with psychotic symptoms or suicidal behavior; 2. A genital anatomical abnormality (such as severe penile fibrosis) or other organic sexual dysfunction with apparent impairment of erection; 3. Erectile dysfunction due to organic disease; 4. Unwilling to stop other patients for depression or erectile dysfunction therapy; 5. A person who has allergies or is sensitive to the ingredients of this test; 6. Combined with severe primary liver and kidney diseases, aspartate aminotransferase , Alanine aminotransferase exceeded 1.5 times the normal value, and creatinine exceeded the normal limit; 7. A patient with severe somatic disease; 8. Patients who have participated in other clinical trials in the past four weeks; 9. A history of drug abuse or alcoholism; 10. The researchers believe that patients who are not eligible for clinical trials are not eligible for clinical trials.

Design outcomes

Primary

MeasureTime frameDescription
change of The international index of erectile function (IIEF-5) total scorefrom baseline to endpoint(Week 8)Each follow-up according to recent life situation, choose the best option for the 5 question, each item is scored 0-5,the total score of 5-7 divided into severe Erectile dysfunction, 8-11 divided into moderate Erectile dysfunction, 12-21 divided into mild Erectile dysfunction, 22-25 for not suffering from Erectile dysfunction (normal)
change of Montgomery Depression Rating Scale(MADRS)total scorefrom baseline to endpoint(Week 8)Montgomery Depression Rating Scale includes 10 items, each item is scored 0-6 , extreme depression: MADRS≥35; severe depression: 35\> MADRS≥30; moderate depression: 30\> MADRS ≥ 22;Mild depression: 22\> MADRS ≥ 12; remission: MADRS \<12.

Secondary

MeasureTime frameDescription
The change of total score of Hamilton Anxiety Scale (HAMA)from baseline to endpoint(Week 8)Each time the follow-up score was based on the contents of the scale,Each item is scored 0-4(0=Asymptomatic,4=extreme)
Change of traditional Chinese medicine syndrome integralfrom baseline to endpoint(Week 8)Each time the follow-up score was based on the contents of the scale,Tongue pulse does not score
A change in the effect of individual symptomsfrom baseline to endpoint(Week 8)Changes in each individual item of the scale were collected at each follow-up visit

Contacts

Primary Contactlili zhang
1078002120@qq.com010-58462584
Backup Contactyingbo zhao
61773582@qq.com13517212347

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026